drugset / Trial / NCT07459751
A Global Phase II/III Clinical Study to Evaluate the Efficacy and Safety of HLX43 Monotherapy or HLX43 in Combination With HLX07 Versus Docetaxel in Advanced or Metastatic Squamous Non-Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
This is a randomized, open-label, multi-center, global phase II/III clinical study to evaluate the efficacy and safety of HLX43 monotherapy or HLX43 in combination with HLX07 vs. docetaxel in the treatment of advanced squamous NSCLC after failure of first-line treatment.
Timeline
- Start
- 2026-05-27
- Primary completion
- 2030-01-15
- Completion
- 2030-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | — | Intravenous |
| Subject | HLX43 | Other / unclassified | — | Intravenous |
| Subject | PIMURUTAMAB | Monoclonal antibody | — | Intravenous |